Literature DB >> 23969705

Topical treatment of neuropathic pain.

Vince Vadurri1.   

Abstract

Pikes Peak Hospice and Palliative Care, Inc., provides care for more than 200 patients with terminal disease who reside at home, in long-term care facilities, in assisted living facilities, or in its acute-care Inpatient Unit. Over the past 4 years, its pharmacy has evolved to provide individualized compounded preparations to meet the unique and complex needs of these patients. An integral part of this evolution was development and implementation of topical treatment for pain. These patients often have multiple medical conditions and complicated health issues. Nearly 50% of patients in the care of Pikes Peak Hospice receive a topical compound to treat any of a variety of conditions, including neuropathies, muscle skeletal pain, wound pain, agitation, and anxiety. Topical compounds give practitioners another option in managing patient maladies and, in many instances, compounded topicals have proven as effective, if not more effective, than commercially available products. In some cases, patients have been able to stop oral pain medications or reduce their dose because the topical preparation is so effective. All in all, the topical preparations described in this article have been invaluable to our patients' comfort and an indispensable option for practitioners.

Entities:  

Year:  2008        PMID: 23969705

Source DB:  PubMed          Journal:  Int J Pharm Compd        ISSN: 1092-4221


  2 in total

Review 1.  Scoping Review of Off-Label Topical Analgesia in Palliative, Hospice and Cancer Care: Towards Flexibility in Evidence-Based Medicine.

Authors:  Baraa O Tayeb; Jennifer A Winegarden; Rawabi A Alashari; Moudi Alasmari; Jonathan Winegarden; Faisal Boker; Abdulaziz Halawi; Amy Lapidow; Ylisabyth S Bradshaw; Daniel B Carr
Journal:  J Pain Res       Date:  2021-09-22       Impact factor: 3.133

2.  Transdermal lidocaine and ketamine for neuropathic pain: a study of effectiveness and tolerability.

Authors:  Emily Tam; Andrea D Furlan
Journal:  Open Neurol J       Date:  2012-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.